ArticleTranslational cancer research2021

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis.

Chenli Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.